17β-estradiol reduces cardiac hypertrophy mediated through the up-regulation of PI3K/Akt and the suppression of calcineurin/NF-AT3 signaling pathways in rats

Chieh Hsi Wu, Jer Yuh Liu, Jia Ping Wu, Yi Hsien Hsieh, Chung Jung Liu, Jin Ming Hwang, Shin Da Lee, Li Mien Chen, Mu Hsin Chang, Wei Wen Kuo, Jyh Cherng Shyu, Jen Hsiang Tsai, Chih Yang Huang

研究成果: 雜誌貢獻文章

23 引文 (Scopus)

摘要

This study was designed to determine the effects of 17β-estradiol (E2) in overcoming the cardiac over-loading and cardiac fibrosis in rats. E2 (100 ng/kg) or oil was applied in female Sprague-Dawley rats with or without bilateral ovariectomy and with or without coarctation of the abdominal aorta after 4 or 8 days. By post-operative day 4, the heart weight, the left ventricular weight, the latent form of MMP-2 in rat hearts with or without the ovary intact had significantly increased while these changes were reversed after E2 treatment. Although animals with the ovaries intact overcame the hypertrophic effects and the consumption of MMP-2, these effects were not restored in ovariectomized animals in which more fibrosis could be found by day 8. Among the IGF-I signaling, the levels of IGF-I, the activities of PI3K-Akt for cardiomyocyte survival, and MEK-ERKs for non-cardiomyocyte proliferation pathways had significantly increased by day 4. These increasing trends were enhanced by E2 treatment. However, down-regulation was only observed on day 8 in ovariectomized animals. Similarly, elevated expressions of the steady-state mRNA of IGF-I, IGF-IR, and Cox vb were observed on day 4 in animals with the ovaries intact and these expressions were enhanced by E2 treatment. In contrast, down-regulation on day 8 in ovariectomized animals was not enhanced by E2. The calcineurin/NFAT-3 pathway was suppressed on day 4 but was elevated on day 8 in ovariectomized animals. These findings indicate that signaling pathways may be plausible mechanisms for the cardiac protective effects of E2 administration.

原文英語
頁(從 - 到)347-356
頁數10
期刊Life Sciences
78
發行號4
DOIs
出版狀態已發佈 - 十二月 12 2005
對外發佈Yes

指紋

Calcineurin
Cardiomegaly
Phosphatidylinositol 3-Kinases
Rats
Estradiol
Animals
Up-Regulation
Insulin-Like Growth Factor I
Ovary
Matrix Metalloproteinases
Fibrosis
Down-Regulation
Weights and Measures
Aortic Coarctation
Abdominal Aorta
Mitogen-Activated Protein Kinase Kinases
Ovariectomy
Cardiac Myocytes
Sprague Dawley Rats
Oils

ASJC Scopus subject areas

  • Pharmacology

引用此文

17β-estradiol reduces cardiac hypertrophy mediated through the up-regulation of PI3K/Akt and the suppression of calcineurin/NF-AT3 signaling pathways in rats. / Wu, Chieh Hsi; Liu, Jer Yuh; Wu, Jia Ping; Hsieh, Yi Hsien; Liu, Chung Jung; Hwang, Jin Ming; Lee, Shin Da; Chen, Li Mien; Chang, Mu Hsin; Kuo, Wei Wen; Shyu, Jyh Cherng; Tsai, Jen Hsiang; Huang, Chih Yang.

於: Life Sciences, 卷 78, 編號 4, 12.12.2005, p. 347-356.

研究成果: 雜誌貢獻文章

Wu, CH, Liu, JY, Wu, JP, Hsieh, YH, Liu, CJ, Hwang, JM, Lee, SD, Chen, LM, Chang, MH, Kuo, WW, Shyu, JC, Tsai, JH & Huang, CY 2005, '17β-estradiol reduces cardiac hypertrophy mediated through the up-regulation of PI3K/Akt and the suppression of calcineurin/NF-AT3 signaling pathways in rats', Life Sciences, 卷 78, 編號 4, 頁 347-356. https://doi.org/10.1016/j.lfs.2005.04.077
Wu, Chieh Hsi ; Liu, Jer Yuh ; Wu, Jia Ping ; Hsieh, Yi Hsien ; Liu, Chung Jung ; Hwang, Jin Ming ; Lee, Shin Da ; Chen, Li Mien ; Chang, Mu Hsin ; Kuo, Wei Wen ; Shyu, Jyh Cherng ; Tsai, Jen Hsiang ; Huang, Chih Yang. / 17β-estradiol reduces cardiac hypertrophy mediated through the up-regulation of PI3K/Akt and the suppression of calcineurin/NF-AT3 signaling pathways in rats. 於: Life Sciences. 2005 ; 卷 78, 編號 4. 頁 347-356.
@article{5e592ed6cdca4f21949cf17ee41ea164,
title = "17β-estradiol reduces cardiac hypertrophy mediated through the up-regulation of PI3K/Akt and the suppression of calcineurin/NF-AT3 signaling pathways in rats",
abstract = "This study was designed to determine the effects of 17β-estradiol (E2) in overcoming the cardiac over-loading and cardiac fibrosis in rats. E2 (100 ng/kg) or oil was applied in female Sprague-Dawley rats with or without bilateral ovariectomy and with or without coarctation of the abdominal aorta after 4 or 8 days. By post-operative day 4, the heart weight, the left ventricular weight, the latent form of MMP-2 in rat hearts with or without the ovary intact had significantly increased while these changes were reversed after E2 treatment. Although animals with the ovaries intact overcame the hypertrophic effects and the consumption of MMP-2, these effects were not restored in ovariectomized animals in which more fibrosis could be found by day 8. Among the IGF-I signaling, the levels of IGF-I, the activities of PI3K-Akt for cardiomyocyte survival, and MEK-ERKs for non-cardiomyocyte proliferation pathways had significantly increased by day 4. These increasing trends were enhanced by E2 treatment. However, down-regulation was only observed on day 8 in ovariectomized animals. Similarly, elevated expressions of the steady-state mRNA of IGF-I, IGF-IR, and Cox vb were observed on day 4 in animals with the ovaries intact and these expressions were enhanced by E2 treatment. In contrast, down-regulation on day 8 in ovariectomized animals was not enhanced by E2. The calcineurin/NFAT-3 pathway was suppressed on day 4 but was elevated on day 8 in ovariectomized animals. These findings indicate that signaling pathways may be plausible mechanisms for the cardiac protective effects of E2 administration.",
keywords = "17β-estradiol, Abdominal aorta coarctation, Calcineurin/NFAT-3 pathway IGF-I signaling, Left ventricle hypertrophy",
author = "Wu, {Chieh Hsi} and Liu, {Jer Yuh} and Wu, {Jia Ping} and Hsieh, {Yi Hsien} and Liu, {Chung Jung} and Hwang, {Jin Ming} and Lee, {Shin Da} and Chen, {Li Mien} and Chang, {Mu Hsin} and Kuo, {Wei Wen} and Shyu, {Jyh Cherng} and Tsai, {Jen Hsiang} and Huang, {Chih Yang}",
year = "2005",
month = "12",
day = "12",
doi = "10.1016/j.lfs.2005.04.077",
language = "English",
volume = "78",
pages = "347--356",
journal = "Life Sciences",
issn = "0024-3205",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - 17β-estradiol reduces cardiac hypertrophy mediated through the up-regulation of PI3K/Akt and the suppression of calcineurin/NF-AT3 signaling pathways in rats

AU - Wu, Chieh Hsi

AU - Liu, Jer Yuh

AU - Wu, Jia Ping

AU - Hsieh, Yi Hsien

AU - Liu, Chung Jung

AU - Hwang, Jin Ming

AU - Lee, Shin Da

AU - Chen, Li Mien

AU - Chang, Mu Hsin

AU - Kuo, Wei Wen

AU - Shyu, Jyh Cherng

AU - Tsai, Jen Hsiang

AU - Huang, Chih Yang

PY - 2005/12/12

Y1 - 2005/12/12

N2 - This study was designed to determine the effects of 17β-estradiol (E2) in overcoming the cardiac over-loading and cardiac fibrosis in rats. E2 (100 ng/kg) or oil was applied in female Sprague-Dawley rats with or without bilateral ovariectomy and with or without coarctation of the abdominal aorta after 4 or 8 days. By post-operative day 4, the heart weight, the left ventricular weight, the latent form of MMP-2 in rat hearts with or without the ovary intact had significantly increased while these changes were reversed after E2 treatment. Although animals with the ovaries intact overcame the hypertrophic effects and the consumption of MMP-2, these effects were not restored in ovariectomized animals in which more fibrosis could be found by day 8. Among the IGF-I signaling, the levels of IGF-I, the activities of PI3K-Akt for cardiomyocyte survival, and MEK-ERKs for non-cardiomyocyte proliferation pathways had significantly increased by day 4. These increasing trends were enhanced by E2 treatment. However, down-regulation was only observed on day 8 in ovariectomized animals. Similarly, elevated expressions of the steady-state mRNA of IGF-I, IGF-IR, and Cox vb were observed on day 4 in animals with the ovaries intact and these expressions were enhanced by E2 treatment. In contrast, down-regulation on day 8 in ovariectomized animals was not enhanced by E2. The calcineurin/NFAT-3 pathway was suppressed on day 4 but was elevated on day 8 in ovariectomized animals. These findings indicate that signaling pathways may be plausible mechanisms for the cardiac protective effects of E2 administration.

AB - This study was designed to determine the effects of 17β-estradiol (E2) in overcoming the cardiac over-loading and cardiac fibrosis in rats. E2 (100 ng/kg) or oil was applied in female Sprague-Dawley rats with or without bilateral ovariectomy and with or without coarctation of the abdominal aorta after 4 or 8 days. By post-operative day 4, the heart weight, the left ventricular weight, the latent form of MMP-2 in rat hearts with or without the ovary intact had significantly increased while these changes were reversed after E2 treatment. Although animals with the ovaries intact overcame the hypertrophic effects and the consumption of MMP-2, these effects were not restored in ovariectomized animals in which more fibrosis could be found by day 8. Among the IGF-I signaling, the levels of IGF-I, the activities of PI3K-Akt for cardiomyocyte survival, and MEK-ERKs for non-cardiomyocyte proliferation pathways had significantly increased by day 4. These increasing trends were enhanced by E2 treatment. However, down-regulation was only observed on day 8 in ovariectomized animals. Similarly, elevated expressions of the steady-state mRNA of IGF-I, IGF-IR, and Cox vb were observed on day 4 in animals with the ovaries intact and these expressions were enhanced by E2 treatment. In contrast, down-regulation on day 8 in ovariectomized animals was not enhanced by E2. The calcineurin/NFAT-3 pathway was suppressed on day 4 but was elevated on day 8 in ovariectomized animals. These findings indicate that signaling pathways may be plausible mechanisms for the cardiac protective effects of E2 administration.

KW - 17β-estradiol

KW - Abdominal aorta coarctation

KW - Calcineurin/NFAT-3 pathway IGF-I signaling

KW - Left ventricle hypertrophy

UR - http://www.scopus.com/inward/record.url?scp=27744442855&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27744442855&partnerID=8YFLogxK

U2 - 10.1016/j.lfs.2005.04.077

DO - 10.1016/j.lfs.2005.04.077

M3 - Article

C2 - 16183079

AN - SCOPUS:27744442855

VL - 78

SP - 347

EP - 356

JO - Life Sciences

JF - Life Sciences

SN - 0024-3205

IS - 4

ER -